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ABSTRACT

Background: A previous analysis of the placebo arm of the Prostate Cancer Prevention
Trial (PCPT) reported 82% overall prevalence of intraprostatic inflammation and identified
a link between inflammation and higher-grade prostate cancer and serum PSA. Here we
studied these associations in the PCPT finasteride arm.
Methods: Prostate cancer cases (N=197) detected either on a clinically indicated biopsy
or on protocol-directed end-of-study biopsy, and frequency-matched controls (N=248) with
no cancer on an end-of-study biopsy were sampled from the finasteride arm. Inflammation
in benign prostate tissue was visually assessed using digital images of H&E stained
sections. Logistic regression was used for statistical analysis.
Results: In the finasteride arm, 91.6% of prostate cancer cases and 92.4% of controls had
at least one biopsy core with inflammation in benign areas; p < 0.001 for difference
compared to placebo arm. Overall, the odds of prostate cancer did not differ by prevalence
(OR=0.90, 95% CI 0.44-1.84) or extent (P-trend=0.68) of inflammation. Inflammation was
not associated with higher-grade disease (prevalence: OR=1.07, 95% CI 0.43-2.69).
Furthermore, mean PSA concentration did not differ by the prevalence or extent of
inflammationin either cases or controls.
Conclusion: The prevalence of intraprostatic inflammation was higher in the finasteride
than placebo arm of the PCPT, with no association with higher-grade prostate cancer.
Impact: Finasteride may attenuate the association between inflammation and highergrade prostate cancer. Moreover, the missing link between intraprostatic inflammation and
PSA suggests that finasteride may reduce inflammation-associated PSA elevation.

Introduction
A recent analysis in the placebo arm of the Prostate Cancer Prevention Trial
(PCPT) indicated a greater prevalence and extent of intraprostatic inflammation in benign
prostate tissue of higher-grade prostate cancer cases than controls (1). The PCPT was a
placebo-controlled, randomized clinical trial studying whether finasteride, a drug that
inhibits the conversion of testosterone into the more potent androgen dihydrotestosterone
in the prostate, could decrease the risk of prostate cancer in men initially at low to
moderate risk of the disease. Finasteride has been reported to reduce symptoms of type
IIIa chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) (2), a condition associated
with intraprostatic inflammation, and possibly also those of bacterial prostatitis (3).
However, it is currently unknown how finasteride affects the prevalence and extent of
intraprostatic inflammation and whether it affects the association between inflammation
and prostate cancer risk, including higher-grade disease.
We had 3 a priori hypotheses concerning finasteride’s effect on intraprostatic
inflammation: 1) less inflammation because of a possible reduction of CP/CPPS symptoms
during finasteride treatment (2), 2) absolute increase in inflammation in response to
finasteride-mediated epithelial cell death and prostate shrinkage (4), or 3) proportional
increase in inflammation based on the prostate volume reduction causing the same
number of immune cells to cover a larger portion of the remaining prostate tissue.
Thus, we performed a case-control study nested in the finasteride arm of the PCPT
to evaluate the association between intraprostatic inflammation and prostate cancer risk
during finasteride treatment. A unique feature of PCPT was that all men underwent annual
prostate-specific antigen (PSA) screening and digital-rectal examination (DRE), and men
not diagnosed with prostate cancer by the end of the 7-year follow-up period were asked
to undergo an end-of-study prostate biopsy irrespective of whether they had a clinical

indication, that is, suspicion of prostate cancer (5). Consequently, tissue was available
from both prostate cancer cases and from cancer-free controls.

Materials and Methods
Study population and design
We studied a subset of men who participated in the multisite PCPT (5). The trial
included men who were ≥55 years; had no abnormalities detected on DRE and had PSA
value ≤3 ng/mL and no to moderate lower urinary tract symptoms (American Urological
Association Symptom Index <20) at baseline. A total of 18,882 men were enrolled in the
trial between 1993 and 1997 and were randomized to receive finasteride (5 mg/day) or
placebo for 7 years. At trial entry, participant weight and height were measured for
calculation of body mass index (BMI; kg/m2). Additionally, participants completed a
questionnaire, which included questions on demographics, lifestyle, and medical factors,
such as cigarette smoking history, first-degree family history of prostate cancer, and
history of diabetes.
During follow-up, participants were screened annually for prostate cancer by PSA
and DRE. The PSA threshold for prostate biopsy was 4 ng/mL. To ensure equal
percentage of prostate biopsies in both study arms, the measured PSA values were
initially doubled for finasteride-treated men, and from the beginning of the fourth year in
the study a multiplying factor of 2.3 was used. If either PSA or DRE was abnormal, men
were recommended for prostate biopsy. Cancers detected on a biopsy done for clinical
suspicion of prostate cancer were termed “for-cause" biopsy detected cases. To catch
cancer cases missed because of finasteride’s PSA lowering effect, all men in both arms of
the trial who were not diagnosed with prostate cancer during the trial were requested to
undergo prostate biopsy after seven years on the trial irrespective of their PSA

concentration or DRE status (5). Cancers detected on these biopsies were considered to
be for-cause biopsy detected if the man had an elevated PSA or abnormal DRE,
otherwise, these cancers were considered to be end-of-study biopsy detected.
Pathologic evaluation of the prostate biopsy cores, including evaluation of Gleason
sum, was confirmed at the Prostate Diagnostic Laboratory at the University of Colorado;
pathologists were blinded to the trial arm and exposure information (5).
Adherence (whether the participant was on or off finasteride) and compliance to
finasteride (the proportion of doses used) were checked biannually at research visits for
reissuing of medication and counting of remaining finasteride doses (5).
The PCPT was approved by the institutional review boards at each trial site. This
study on inflammation was approved by the Johns Hopkins Bloomberg School of Public
Health Institutional Review Board and by the Colorado Multiple Institutional Review Board.

Prostate cancer cases and controls
To create a case-control study for evaluation of intraprostatic inflammation we used
a sub-sample of a previously developed case-control study nested in the PCPT that
included all 1,809 eligible men diagnosed with prostate cancer (cases) either on for-cause
or end-of-study biopsy, and a sample of 1,809 men who were negative for prostate cancer
on end-of-study biopsy (controls) (6). To enrich the population for non-white men, all 372
non-white men were included in the control group, and 1,437 men were sampled from the
white men without prostate cancer to achieve the target of 1,809 controls. Controls were
frequency matched to cases on age at baseline, first-degree family history of prostate
cancer at baseline, and treatment arm.
For the inflammation study 197 cases from the finasteride arm of the PCPT were
selected from the larger case-control population. To enhance statistical efficiency, we

sampled approximately equal numbers of cases by grade (Gleason sum ≤6; or 7-10) and
biopsy indication (for-cause, end-of-study). Additionally, 248 controls who did not have
cancer at end-of-study biopsy were sampled from the finasteride arm.

Assessment of inflammation in benign prostate tissue from biopsies
The H&E stained slides of the prostate biopsies used for prostate cancer diagnosis
during the PCPT were reviewed for inflammation. For each man, 6-10 needle biopsy cores
were usually taken. Multiple cores were mounted on each slide. We sampled a median of
2 slides per man, yielding, on average, 3.3 biopsy cores per man. Cores were mainly from
the apex or mid-gland.
In both cases and controls, we evaluated inflammation in only the benign areas of
the biopsy cores. To blind the pathologist to case-control status, all areas of
adenocarcinoma (cases) and arbitrary benign areas on cores without cancer (cases and
controls) were masked with ink on the slide cover slips (1). We used the Aperio
ScanScope slide scanner (Aperio, Vista, CA) to digitally image the H&E stained slides.
Slide images were uploaded into the Spectrum Digital Pathology Information Management
System (Aperio, Vista, CA) and were visually reviewed for inflammation online using the
Aperio ImageScope Viewer Software package.
Assessment of inflammation in benign tissue in the PCPT has been described in
detail previously (1). In short, the following aspects were evaluated: 1) the presence of any
inflammatory cells, any acute inflammatory cells (e.g., polymorphonuclear cells), and any
chronic inflammatory cells (e.g., cells with an appearance consistent with that of
lymphocytes and macrophages) in the benign tissue for each biopsy core on each slide; 2)
the proportion of the total benign (unmasked) biopsy core area per slide that had
involvement of any inflammatory cells, either acute inflammatory cells, or chronic

inflammatory cells; and 3) an inflammation score using a modified version of the
histopathological classification system developed by Nickel et al. (7). For the latter, the
extent (1=focal, 2=multifocal, 3=diffuse) and grade (1=mild, 2=moderate, 3=severe) of
inflammation present was recorded separately for the luminal, intraepithelial, and stromal
compartments of the benign prostate tissue on each slide. All of the images for this study
were reviewed by a single pathologist (BG), who was trained to score inflammation using
these methods.

Statistical analysis
We used linear regression with model adjustment for baseline age, family history of
prostate cancer, and race to calculate adjusted means and proportions for population
characteristics, measures of inflammation, serum PSA, and adherence and compliance to
finasteride use. Logistic regression with the same model adjustments was used to
evaluate statistical significance of the differences between cases and controls.
We used logistic regression to estimate odds ratios (OR) and 95% confidence
intervals (CI) of prostate cancer overall, and separately for higher-grade (Gleason 7-10)
and lower-grade (Gleason 6 or less) prostate cancer by inflammation prevalence (i.e., at
least one biopsy core with inflammation) and extent (i.e., none, some, or all cores with
inflammation). We adjusted for age, family history of prostate cancer, and race. We
performed separate analyses for all men (intention-to-treat analysis) and for men on
finasteride at the time of biopsy to evaluate the biological effect. In further sensitivity
analyses we evaluated the influence of PSA concentration, Gleason sum and compliance
to finasteride (≤75% vs. >75% of the assigned finasteride doses used) on these
associations.

Logistic regression was performed using IBM SPSS statistics 20 statistical software
(Chicago, Illinois, USA). Adjusted means were estimated using STATA version 12
(StataCorp LP, College Station, Texas, USA). All statistical tests are two-sided.

Results

Study Population Characteristics
Due to frequency matching in the parent nested case-control study, the median age
at the trial baseline and the prevalence of family history of prostate cancer were similar
between cases and controls (Table 1). The proportion of non-white men was higher among
controls due to their oversampling in controls. After adjusting for age, family history, and
race, the prevalence of smoking and diabetes, and the median BMI and mean prostate
volume were comparable in cases and controls. The median PSA was higher among
prostate cancer cases compared to controls both at baseline and at the time of biopsy,
with the highest concentration observed in men subsequently diagnosed with higher-grade
prostate cancer (Table 1). As expected given their randomization to the finasteride arm,
PSA concentration decreased between baseline (before finasteride treatment) and biopsy
(after 7 years of treatment) most among controls, but also among prostate cancer cases,
with the exception of higher-grade cases in whom the mean PSA concentration increased
compared to baseline despite finasteride. Adherence and compliance to finasteride use
were lower in cases compared to controls, being lowest in men diagnosed with lowergrade prostate cancer (Table 1).

Prevalence and Extent of Inflammation in Benign Prostate Tissue in Controls
The prevalence and extent of inflammation was examined for all patients in the
finasteride arm (Table 2, All men) as well as for those who were actively taking finasteride
at the time of biopsy (Table 2, Men on finasteride at time of biopsy) The prevalence of
inflammation among controls (men without cancer on end of study biopsy) was 92.4% for
all men in the finasteride arm, and 93.5% in men on finasteride at the time of biopsy (Table
2). Most of the inflammation present was chronic (313 men, 70.3%); of these men, 131

(41.9%) had grade 3 chronic inflammation. In contrast, acute inflammation was observed
only in 34 men (7.6%); of these men, 1 (2.9%) had grade 3 acute inflammation.
Interestingly, the prevalence and extent of inflammation was higher in the finasteride arm
(present study) in the control group (without cancer) than in the placebo arm. For example,
in the controls the number of men with at least one core with inflammation (92.4% on
finasteride vs. 78.2% not on finasteride; p = <.001), and the mean of mean percentage of
tissue area with inflammation (16.4% in the finasteride arm vs. 11.5% in the placebo arm;
p = <.001 ) were both significantly higher in the finasteride arm.

Inflammation and Prostate Cancer Risk
Unlike in the placebo arm (1) no difference in prevalence or extent of inflammation
was observed between cases and controls overall (Table 2) or by location (intraluminal,
stromal or epithelial, data not shown) in the finasteride arm. The exception was a lower
mean percentage of biopsy cores with inflammation, a measure of extent, in lower-grade
cases compared to controls in the intention-to-treat analysis. However, the difference was
no longer significant in men on finasteride at the time of biopsy.
Overall, unlike in the placebo arm there were no statistically significant associations
between prevalence or extent of inflammation and the odds of prostate cancer either in the
intention-to-treat analysis or among men on finasteride (Table 3). An increasing extent of
inflammation was associated with a decreasing odds of lower-grade disease (P-trend
0.03), but only in the intention-to-treat analysis.

Inflammation and PSA Concentration
Serum PSA concentration at the time of biopsy did not differ by the prevalence or

extent of inflammation in either cases or controls (Table 4). This is also in contrast to
findings in the placebo arm (1). The exception was a higher PSA concentration among
men with at least one biopsy core with inflammation compared to men with no biopsy
cores with inflammation among those on finasteride at the time of biopsy (P=0.05).
Having inflammation in all biopsy cores (versus none) was non-significantly
inversely associated with prostate cancer in both men with lower (PSA ≤2 ng/ml, OR 0.73,
95% CI 0.27-2.00) and higher (PSA >2 ng/ml, OR 0.50, 95% CI 0.09-2.88) corrected PSA
concentration. For higher-grade cancer the pattern of association was different from
overall; the OR for having inflammation in all biopsy cores was above 1.0 for men with
PSA >2 ng/ml (OR 1.17, 95% CI 0.17-8.25), but less than 1.0 for men with PSA at ≤2
ng/ml (OR 0.83, 95% CI 0.21-3.28).

Estimated effect of prostate volume shrinkage on intraprostatic inflammation
The overall prevalence of intraprostatic inflammation in the PCPT finasteride arm
was higher compared to the placebo arm (1); the proportion of men with at least one
biopsy core with inflammation was 92.4% vs. 78.2% in the controls and 91.2% vs. 86.2%
in prostate cancer cases, respectively. Also, the mean extent of inflammation (mean of the
mean percentage of tissue area with inflammation) was 5.5% higher in the PCPT
finasteride arm (16.7%) compared to the placebo arm (11.2%) (1). Because finasteride
treatment decreases prostate volume, we calculated how much the extent of inflammation
would increase due to volume reduction if we assume that the absolute amount of
inflammation-affected tissue would remain constant in the prostate. The median prostate
volume was 15% lower in the finasteride arm compared to the placebo arm (25.1 vs. 29.5
cm3, respectively). Therefore, the absolute volume of inflamed tissue in a 30 cm3 prostate
in a man before finasteride treatment is assumed to be 11.2% x 30 cm3 = 3.36 cm3. If the

prostate volume decreased by 15%, the new volume would be 0.85 x 30 cm3 = 25.5 cm3.
Therefore, the extent of the same amount of inflamed tissue in lower volume prostate
would be 3.36 cm3/25.5 cm3=13.1%, which is 1.9% higher than the assumed original
extent of 11.2%. Thus, the expected percentage of tissue with inflammation that would be
due to gland shrinkage (13.1%) is lower than the observed extent (16.7%).

Discussion
In the finasteride arm of the PCPT, we observed a high prevalence and extent of
inflammation in benign prostate tissue, but did not observe any association between
intraprostatic inflammation and the risk of total or higher-grade prostate cancer. Further,
intraprostatic inflammation was not associated with serum PSA concentration in these
finasteride-treated men. Previously published results from the PCPT placebo arm
reported 86% and 78% prevalence of intraprostatic inflammation among prostate cancer
cases and controls, respectively, with highest prevalence being observed in cases with
higher-grade disease(1). We show that in the finasteride arm the overall prevalence of
intraprostatic inflammation was higher, the observed positive association with risk of total
and higher-grade cancer was fully attenuated, and the observed positive association
between finasteride-associated inflammation and PSA was missing.
Finasteride treatment induces both apoptosis and a reduction in cellular volume
(hormonal atrophy) in the prostate (8), which leads to overall prostate volume reduction.
Androgens and androgen deprivation therapy influence the immune system both
systemically (9) and locally (10). Local prostate effects are characterized by an increased
number of macrophages, dendritic cells, and T-cells in the tissue (10). Androgen ablation
makes normally tolerant T-cells recognize prostate antigens and proliferate in response to
them (4). Although we did not assess specific types of inflammatory cells present, the
markedly elevated prevalence of intraprostatic inflammation in the finasteride arm relative
to the placebo arm suggests that similar effects result also from local androgen inhibition in
the prostate in response to 5α-reductase inhibition. This is supported by an even higher
prevalence of inflammation in men still on finasteride at the time of biopsy.
To determine whether the hypothesis of absolute or proportional increase in
inflammation is more likely, we considered the possible effect of prostate volume reduction

during finasteride treatment on extent of inflammation. This analysis indicated that while
some of the increase in inflammatory cells could be the result of gland shrinkage, the
estimated increase in inflammation extent due to overall volume decrease by finasteride
does not entirely explain the greater extent of intraprostatic inflammation in finasteridetreated men compared to the placebo arm. Instead, our findings suggest that finasteride
treatment induces intraprostatic inflammation as has been previously reported for other
types of androgen deprivation (9,10).
Unlike in the previous study in the PCPT placebo arm (1), we did not observe an
association between intraprostatic inflammation and risk of prostate cancer overall or
higher-grade disease in the finasteride arm. This may be because the high prevalence of
inflammation in finasteride-treated men makes comparisons underpowered given our
sample size, or because chronic finasteride-associated inflammation is not a prostate
cancer risk factor as it is in placebo-treated men. The latter notion is supported by the lack
of an association between finasteride-associated inflammation and PSA level;
inflammation induced by finasteride treatment may not cause such damage to prostate
epithelial cells that would allow PSA to leak into circulation, or finasteride treatment may
attenuate the cytotoxic effects of inflammation. The immune cells induced to infiltrate the
prostate during finasteride therapy may not be pro-carcinogenic; in fact they may be antitumorigenic (10). Inflammation observed in the placebo arm may also reflect more longstanding and etiologically relevant inflammation, whereas finasteride-induced inflammation
could have started only after PCPT randomization, at maximum seven years earlier.
Further research will be needed to clarify which of these speculations, if any, is
explanatory.
The lack of an association between finasteride-associated inflammation and PSA
also has implications for the accuracy of PSA as a tumor marker. If benign causes of PSA

elevation, such as intraprostatic inflammation, are removed by finasteride treatment, the
performance of PSA would be enhanced as a prostate cancer tumor marker.
Concordantly, an earlier PCPT analysis reported improved sensitivity of PSA to detect
prostate cancer during finasteride treatment (11). In the current analysis, PSA was
decreased at prostate biopsy as compared with the baseline level obtained before starting
finasteride, except in those later diagnosed with higher-grade cancer. This observation
suggests that PSA elevation is more specific to higher-grade prostate cancer during
finasteride therapy.
We observed a possible inverse association between extent of finasterideassociated inflammation and risk of lower-grade prostate cancer. This finding was not
explained by differing likelihood of a prostate biopsy as the association was also inverse
even in men with a low corrected PSA (≤2 ng/ml). We also observed that lower-grade
cases had a lower prevalence and extent of inflammation than controls; these differences
were attenuated when restricting to men on finasteride at the time of biopsy.
Our study has several unique strengths. Prostate cancer screening and diagnosis
were standardized by the PCPT study protocol, and tumor diagnosis and Gleason sum
were confirmed by central pathological review. The pathologist who assessed
inflammation in all biopsy cores was trained to evaluate inflammation by a consensusdeveloped system (7), and was fully blinded to case-control status and treatment arm,
which reduces the potential for observation bias. We also had the unique opportunity to
evaluate the association between intraprostatic inflammation and prostate cancer risk in
men with very low PSA, allowing evaluation of biological effects in the prostate without the
possible detection bias due to inflammation affecting PSA level and likelihood for prostate
biopsy.

Our study also has some limitations. Although PCPT was a prospective randomized
trial, our current nested case-control study was a retrospective analysis. Inflammation in
prostate cancer tissue was evaluated only at one time-point (time of biopsy) and we could
not evaluate time trends in intraprostatic inflammation during finasteride usage. Further,
we could not determine whether inflammation in benign tissues of cancer cases was due
to the tumor or vice versa. Prostate biopsies are taken mainly from the peripheral zone of
the prostate where malignancy usually occurs. We could not determine whether
inflammation in central areas (e.g. the transition zone) of the prostate is associated with
prostate cancer risk. Participants of the PCPT trial were selected to be men with low risk of
prostate cancer at baseline, and were screened yearly for the entire duration of the trial.
Thus, we could not evaluate associations between inflammation and metastatic prostate
cancer at diagnosis or prostate cancer death. Finally, due to low number of non-white men
we could not evaluate the association between intraprostatic inflammation and prostate
cancer separately by race.
In conclusion, we found that men using finasteride have an increased prevalence
and extent of intraprostatic inflammation compared to men not using finasteride.
Nevertheless, finasteride-associated inflammation was not associated with risk of highergrade prostate cancer or PSA in contrast to findings in the PCPT placebo arm. Finasteride
may improve the accuracy of PSA as a tumor marker, if it does indeed minimize PSA
elevation due to inflammation. Future studies will need to address whether increased
inflammation in finasteride-treated men is due to sustained cell death and hormonal
atrophy in prostate tissue, and whether intraprostatic inflammation is associated with
metastatic or fatal prostate cancer.
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Table 1. Characteristics* of prostate cancer cases and controls**, finasteride arm, Prostate Cancer Prevention Trial
Controls
Total
N
Mean age at baseline (years)
Mean age at biopsy (years)
Non-white; n (%)
Family history; n (%)
Cigarette smoking history; n (%)
Current
Former
Never
Mean pack-years smoked, current and former smokers
Mean body mass index (kg/m2)
History of diabetes; n (%)
Mean prostate volume (cc)
Mean PSA***
Concentration at baseline (ng/mL)
Concentration at biopsy (ng/mL)
Mean annual change in PSA (ng/mL/year)
Adherence to finasteride use; n (%)
Mean compliance with finasteride treatment (%)

Prostate cancer cases
Lower grade
Higher grade
(Gleason 6 or
(Gleason 7-10)
less)
97
100
64
65
71
72
10 (10.3)#
11 (11.0)#
22 (22.7)
19 (19.0)

248
64
74
60 (24.2)
53 (21.4)

197
64
71
21 (10.7)#
41 (20.8)

16 (6.5)
144 (58.1)
88 (35.5)
13.8
27.9
16 (6.5)
27.3

11 (5.6)
120 (60.9)
66 (33.5)
14.4
27.5
10 (5.1)
26.2

3 (3.1)
57 (58.8)
37 (38.1)
14.4
27.3
4 (4.1)
26.1

8 (8.0)
63 (63.0)
29 (29.0)
14.6
27.7
6 (6.0)
26.4

1.10
0.54
-0.62
231 (93.1)
91.8

1.50#
1.28#
-0.07#
170 (86.3)#
85.5

1.43#
1.28#
-0.30#
82 (84.5)#
82.5

1.56#
1.49#
0.16#
88 (88.0)
88.4

*For all characteristics except baseline age, family history of prostate cancer, and race, values were calculated by generalized linear models (linear for
adjusted proportions and means and logistic for P-values) adjusting for baseline age, family history, and race.
**In the parent nested case-control study, cases and controls were frequency matched on baseline age and family history. All non-white controls were
sampled. For this tissue-based study, cases were sampled from the finasteride arm of the trial so that half were higher grade (Gleason sum ≥7) and half were
lower grade (Gleason sum <7), and of these half were detected on a biopsy performed for an elevated PSA or an abnormal digital-rectal examination (forcause biopsy) and half were detected on a biopsy performed at the end of the trial per trial protocol (end-of-study biopsy). Controls were sampled from men
who were negative for prostate cancer on the biopsy performed at the end of the trial per protocol.
*** Uncorrected PSA concentrations (see Methods)
#P<0.05 compared with controls.

Table 2. Prevalence and extent* of inflammation assessed in benign prostate tissue from biopsy cores in prostate cancer cases overall and by grade and
controls**, finasteride arm of the Prostate Cancer Prevention Trial
All men
Controls
Total
N

At least one biopsy core with inflammation
(%)***
Mean of the percentage of biopsy cores with
inflammation***
Mean of the mean percentage of tissue area
with inflammation****
Overall
In men with at least one biopsy core with
inflammation

Prostate cancer
cases
Grade
Lower
Higher
grade
grade
97
100

Men on finasteride at the time of biopsy
Controls
Prostate cancer cases
Total

Grade

231

170

Lower
grade
82

92.7

93.5

92.9

93.9

92.0

62.1#

73.0

72.0

70.3

66.7

73.7

17.0

14.6

19.0

16.8

17.8

15.3

20.1

18.5

16.3

20.4

18.0

19.1

16.3

21.8

248

197

92.4*****

91.6*****

90.2

71.0

67.7

16.4
17.7

Higher
grade
88

*From generalized linear models (linear for adjusted proportions and means, logistic for P-values) adjusting for baseline age, family history of prostate cancer,
and race.
** In the parent nested case-control study, cases and controls were frequency matched on baseline age and family history of prostate cancer. All non-white
controls were sampled. For this tissue-based study, cases were sampled from the finasteride arm of the trial so that half were higher grade (Gleason sum ≥7)
and half were lower grade (Gleason sum <7), and of these half were detected on a biopsy performed for an elevated PSA or an abnormal digital-rectal
examination (for-cause biopsy) and half were detected on a biopsy performed at the end of the trial per trial protocol (end-of-study biopsy). Controls were
sampled from men who were negative for prostate cancer on the biopsy performed at the end of the trial per protocol.
***For each man, the denominator is total number of biopsy cores evaluated.
****For each man, the denominator is total benign tissue area across all biopsy cores evaluated on each of the man’s slides.
***** The prevalences in the PCPT placebo arm were 78.2% in controls and 86.2% in cases (1).
#P≤0.05 compared with controls.

Table 3. Association* between inflammation assessed in benign prostate tissue from biopsy cores and prostate cancer risk, overall and by
grade, finasteride arm, Prostate Cancer Prevention Trial
Prostate cancer cases, all

N

Prostate cancer cases, men on finasteride at the time of
biopsy

Total

Lower grade

Higher grade

Total

Lower grade

Higher grade

197

97

100

170

82

88

0.75
0.32-1.75

1.07
0.43-2.69

0.93
0.42-2.08

1.03
0.35-3.02

0.79
0.31-2.06

1.00
Reference

1.00
Reference

1.00
Reference

1.00
Reference

1.00
Reference

1.00
Reference

1.00
0.48-2.09

0.97
0.40-2.32

1.00
0.38-2.58

1.00
0.44-2.31

1.30
0.43-3.91

0.72
0.27-1.93

0.80
0.38-1.68
0.68

0.52
0.21-1.30
0.03

1.16
0.45-3.00
0.57

0.86
0.37-1.98
0.49

0.76
0.25-2.34
0.13

0.87
0.33-2.34
0.77

At least one biopsy core with inflammation

OR
95% CI

0.90
0.44-1.84

Extent of biopsy cores with inflammation

Zero cores
OR
95% CI
Some cores
OR
95% CI
All cores
OR
95% CI
P-trend

*From a logistic regression model adjusting for the matching factors (baseline age and family history of prostate cancer) and for oversampling of non-white
controls. In the parent nested case-control study, cases and controls were frequency matched on baseline age and family history of prostate cancer. All nonwhite controls were sampled. For this tissue-based study, cases were sampled from the finasteride arm of the trial so that half were higher grade (Gleason
sum ≥7) and half were lower grade (Gleason sum <7), and of these half were detected on a biopsy performed for an elevated PSA or an abnormal digitalrectal examination (for-cause biopsy) and half were detected on a biopsy performed at the end of the trial per trial protocol (end-of-study biopsy). Controls
were sampled from men who were negative for prostate cancer on the biopsy performed at the end of the trial per protocol.

Table 4. Mean serum PSA concentration at biopsy* by prevalence and extent of inflammation assessed in benign prostate tissue from biopsy
cores in the controls and prostate cancer cases, finasteride arm, Prostate Cancer Prevention Trial
All men
At least one biopsy
core with
inflammation
CONTROLS
Total (N)
Mean PSA at biopsy
(ng/ml)***
Without indication for
biopsy (N)
Mean PSA at biopsy
(ng/ml)***
CASES
Total (N)
Mean PSA at biopsy
(ng/ml)
Detected on a forcause biopsy (N)
Mean PSA at biopsy
(ng/ml)***
Detected on an end-ofstudy biopsy (N)****
Mean PSA at biopsy
(ng/ml)***

No

Yes

19

229

0.56

0.60

16

217

0.59

0.58

16

181

1.33

1.54

8

90

1.67

2.12

8

91

0.99

0.97

P

0.51

0.74

0.58

0.43

0.92

Extent of
biopsy cores
with
inflammation
Some
All
115

114

0.58

0.61

110

107

0.58

0.58

99

82

1.61

1.46

48

42

2.29

1.91

51

40

0.96

0.99

P-trend**

0.34

0.53

0.74

Men on finasteride at the time of biopsy
At least one
Extent of
biopsy core
biopsy cores
with
with
P
P-trend**
inflammation
inflammation
No
Yes
Some
All
15

216

0.38

0.55

13

206

0.39

0.54

12

158

1.10

1.40

6
0.57

0.90

1.23

0.05

0.06

0.41

82
1.88

6

76

0.98

0.88

0.29

0.63

107

109

0.55

0.55

104

102

0.55

0.52

83

75

1.50

1.28

43

39

2.14

1.58

40

36

0.81

0.95

*From linear regression models adjusting for age at baseline.
**Across no (zero), some, all biopsy cores with inflammation. Reference is men with “No” (zero) biopsy cores with inflammation.
*** Uncorrected PSA concentrations (see Methods)
****Without an indication for biopsy.

0.22

0.48

0.60

0.34

0.55

